Lv5
982 积分 2025-05-16 加入
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
6天前
已完结
Effect of ursodeoxycholic acid on glycemic markers: A systematic review and meta-analysis of clinical trials
26天前
已完结
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
28天前
已完结
Exploring the next generation of antibody–drug conjugates
29天前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
30天前
已完结
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study
1个月前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
1个月前
已完结
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
1个月前
已完结
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
1个月前
已完结
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
